Abiopharma

🔍 Glennan Sean Joseph (Executive)

Company: Hut 8 Corp. (HUT)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 12,355 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,423.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,807 shares of Common Stock at $78.7 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,616.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 638 shares of Common Stock at $79.33 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 17,978.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12,355 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,355.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Reflects restricted stock units ("RSUs") that upon vesting converted into shares of Issuer common stock on a one-for-one basis.
• F2: Reflects shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs, effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 9, 2024.
• F3: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
• F4: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs are settled in either common stock or cash (or a combination thereof) at the discretion of the Issuer.
• F5: These RSUs vest in three equal annual installments beginning on August 21, 2025.